Novartis | NOVN - Debt


Novartis reported $49.01B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Alcon AG USD 5.25B 4.74B Mar/2026
Almirall EUR 342.86M 61.94M Dec/2025
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Autolus Therapeutics Ltd USD 253.44M 8.84M Mar/2025
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Fresenius EUR 11.9B 28M Mar/2026
Fresenius Medical Care EUR 10.96B 66.06M Jun/2026
Genmab DKK 5.35B 5.2B Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
GRIFOLS EUR 8.52B 1.15B Jun/2026
Hikma Pharmaceutical USD 1.6B 46M Dec/2025
J&J USD 54.99B 7.05B Mar/2026
Lakefront Biotherapeutics EUR 6.44M 480K Mar/2026
Lonza CHF 4.71B 915M Dec/2024
Merck EUR 12.04B 86M Mar/2026
Merck USD 49.12B 222M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novartis USD 47B 14.98B Mar/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Orion EUR 330.3M 24.9M Mar/2026
Pfizer USD 63.19B 536M Jun/2026
Philips EUR 7.47B 632M Jun/2026
Recordati EUR 2.31B 57.06M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 23.58B 3.56B Jun/2026
UCB EUR 3.03B 12M Dec/2024